The Bottom LineThe most important thing to take away is that...

The Bottom LineThe most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions. While analysts did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Sarepta Therapeutics after the downgrade.So things certainly aren't looking great, and you should also know that we've spotted some potential warning signs with Sarepta Therapeutics, including concerns around earnings quality

Hi Insulsa
Because I do a great deal of DD I’m confident we have a Blockbuster drug in Atl1102
Example of what I research tells me Sareptas Gene therapy drug $3:2 mill . Is all not roses…

Arjay and mates don’t do any DD and find it hard to understand what PER is capable of.$$